Banner

DR. MANOJ UNNI

Qualification: Fellow in Adult Leukemia and Bone Marrow Transplantation, D.M. (Hematology) , M.D. (General Medicine), M.B.B.S
Designation / Role: Clinical Associate Professor, Dept of Medical Oncology and Hematology at Amrita Institute of Medical Sciences, Cochin
Address: Clinical Associate Professor Dept of Medical Oncology & Hematology, Amrita Institute of Medical Sciences AIMS Ponekkara P O, Cochin-682041, Kerala Phone Off: 91-484-4003003

CLINICAL TRAINING AND PROFESSIONAL EXPERIENCE:

  • Consultant, Department of Hematology – BMT, National Centre for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar (December 2011- November 2016)
  • Fellow in Adult Leukemia, British Columbia Cancer Agency and Vancouver Coastal Health, University of British Columbia, Vancouver, Canada (2009 – 2011)
  • Associate Professor, Dept of Medical Oncology and Hematology, Amrita Institute of Medical Sciences, Cochin, Kerala, India (2008-2009) 
  • Assistant Professor, Dept of Medical Oncology and Hematology, Amrita Institute of Medical Sciences, Cochin, Kerala, India (2006-2008) 
  • Senior Registrar, Christian Medical College, Vellore, Tamilnadu, India (2003-2006)
  • Non PG demonstrator, Christian Medical College, Vellore, Tamilnadu, India (2002-2003)
  • Non PG Registrar, Christian Medical College, Vellore, Tamilnadu, India (2001-2002)
  • Senior Resident, Dept of Medicine, Amrita Institute of Medical Sciences, Cochin, Kerala, India (2000-2001) 
  • Associate Consultant, Dept. of Medicine, Malankara Orthodox Syrian Church Medical Mission Hospital, Kolenchery, Kerala, India (1997-2000)

MAJOR INTERESTS:

  • Stem cell transplantation
  • Adult Hemato-Oncology
  • Benign Hematology

RESEARCH EXPERIENCE:

  • Submitted the MD thesis titled "Mini Mental Status in HIV positive patients (MD Thesis Dec 1996.).
  • Participated in a clinical trial 'Randomized, Controlled, Open-labelled, Multicentre, Comparison of Thalidomide Versus High-Dose Dexamethasone for the treatment of Relapsed, Refractory Multiple Myeloma’.
  • Participated in a clinical trial ‘A Phase I/IIa, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerance, and Preliminary Activity of Intravenous High-Dose Fluphenazine HCl in Patients with Advanced Multiple Myeloma’.
Show more







Account